-$1.06 EPS Expected for Flexion Therapeutics Inc (FLXN) This Quarter

Equities research analysts forecast that Flexion Therapeutics Inc (NASDAQ:FLXN) will announce earnings per share of ($1.06) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Flexion Therapeutics’ earnings. The highest EPS estimate is ($1.04) and the lowest is ($1.08). Flexion Therapeutics posted earnings of ($1.16) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 8.6%. The business is scheduled to announce its next earnings report on Tuesday, August 6th.

On average, analysts expect that Flexion Therapeutics will report full year earnings of ($4.07) per share for the current financial year, with EPS estimates ranging from ($4.18) to ($3.93). For the next year, analysts expect that the business will post earnings of ($2.44) per share, with EPS estimates ranging from ($2.95) to ($1.68). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.13) by $0.04. Flexion Therapeutics had a negative return on equity of 131.94% and a negative net margin of 549.07%. The firm had revenue of $10.56 million during the quarter, compared to the consensus estimate of $11.10 million.

Several analysts have recently commented on FLXN shares. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 10th. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Northland Securities restated a “buy” rating and issued a $20.00 target price on shares of Flexion Therapeutics in a research note on Thursday, May 9th. BidaskClub downgraded Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 13th. Finally, Wells Fargo & Co restated a “buy” rating on shares of Flexion Therapeutics in a research note on Wednesday, April 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $23.71.

In related news, Director C Ann Merrifield purchased 8,000 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was bought at an average price of $12.64 per share, for a total transaction of $101,120.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $126,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael D. Clayman purchased 4,046 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were bought at an average price of $12.36 per share, with a total value of $50,008.56. Following the purchase, the insider now owns 70,856 shares in the company, valued at $875,780.16. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 20,058 shares of company stock worth $249,158. Insiders own 16.01% of the company’s stock.

Hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA increased its stake in shares of Flexion Therapeutics by 53,692.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 6,980 shares during the last quarter. Next Capital Management LLC purchased a new stake in shares of Flexion Therapeutics during the 4th quarter worth approximately $84,000. Advisor Group Inc. increased its stake in shares of Flexion Therapeutics by 68.2% during the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 3,490 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Flexion Therapeutics by 341.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,455 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 8,084 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Flexion Therapeutics during the 1st quarter worth approximately $187,000. Institutional investors own 91.47% of the company’s stock.

Flexion Therapeutics stock traded up $0.22 during trading hours on Friday, reaching $12.74. 570,164 shares of the company’s stock were exchanged, compared to its average volume of 663,964. The company has a current ratio of 6.32, a quick ratio of 6.06 and a debt-to-equity ratio of 2.10. Flexion Therapeutics has a twelve month low of $9.65 and a twelve month high of $29.10. The company has a market cap of $484.03 million, a P/E ratio of -2.84 and a beta of 1.56.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Further Reading: What causes a recession?

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.